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Available online 13 September 2016During development, endothelial cells (EC) display tissue-speciﬁc attributes that are unique to each vascular bed,
as well as generic signaling mechanisms that are broadly applied to create a patent circulatory system.We have
previously utilized human embryonic stem cells (hESC) to generate tissue-speciﬁc EC sub-types (Raﬁi et al.,
2013) and identify pathways that govern growth and trans-differentiation potential of hESC-derived ECs
(James et al., 2010). Here, we elucidate a novel Notch-dependentmechanism that induces endothelial to mesen-
chymal transition (EndMT) in conﬂuent monolayer cultures of hESC-derived ECs. We demonstrate density-de-
pendent induction of EndMT that can be rescued by the Notch signaling inhibitor DAPT and identify a positive
feedback signaling mechanism in hESC-ECs whereby trans-activation of Notch by DLL4 ligand induces elevated
expression and surface presentation of DLL4. Increased Notch activation in conﬂuent hESC-EC monolayer cul-
tures induces areas of EndMT containing transitional cells that are marked by increased Jagged1 expression
and reduced Notch signal integration. Jagged1 loss of function in monolayer hESC-ECs induces accelerated feed-
back stimulation of Notch signaling, increased expression of cell-autonomous, cis-inhibitory DLL4, and EndMT.
These data elucidate a novel interplay of Notch ligands inmodulating pathway activation during both expansion
and EndMT of hESC-derived ECs.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The mammalian heart begins as a linear tube that is comprised to
two cells types - myocardium, the muscle cells that drive mechanical
function, and endocardium, the primary endothelial cell (EC) popula-
tion (Harvey, 2002). In order to form a multi-chambered organ, the
heart tube undergoes “looping” and endocardial cells undergo endothe-
lial to mesenchymal transition (EndMT), migrate into the cardiac jelly
and proliferate to form the cardiac valves and septum (von Gise and
Pu, 2012). EndMThas long been thought to occur exclusively in the con-
text of embryonic cardiogenesis, however, recent studies provide evi-
dence for EndMT in adult tissues that is thought to contribute to the
pathogenesis of many diseases, including pulmonary (Arciniegas et al.,
2005), intestinal (Rieder et al., 2011), kidney (Zeisberg et al., 2008)
and cardiac ﬁbrosis (Zeisberg et al., 2007). As such, the molecular path-
ways that govern EndMT are not only relevant to basic studies of
cardiogenesis, but also may enable targeted therapies that improve
functional perfusion of diseased or injured tissues.Medicine and Infertility, Weill
es.
. This is an open access article underMultiple signaling pathways have been linked to EndMT, including
transforming growth factor beta (TGFβ) (Gonzalez and Medici, 2014),
nitric oxide (NO) (Chang et al., 2011), and ﬁbroblast growth factor
(FGF) (Chen et al., 2012), however, Notch signaling in known to play a
central role in both the demarcation of boundaries within the embryon-
ic vascular network (Benedito et al., 2009) as well as EndMT (Niessen
and Karsan, 2008). The Notch family is comprised of four transmem-
brane receptors (Notch1–4) that are activated by membrane-anchored
ligands Delta-like (DLL) 1, 3 and 4 and Jagged (JAG) 1 and 2. Notch li-
gand on one cell can trans-activate Notch receptor on neighboring
cells, resulting in release of the Notch intracellular domain (NICD) via
proteolytic processing and translocation to the nucleus to activate tran-
scription of downstream targets such as HES and HEY (Guruharsha et
al., 2012). Yet Notch ligands are also capable of inhibiting receptor acti-
vation in the cell they are presented on (cis-inhibition) (de Celis and
Bray, 1997; Klein et al., 1997; Micchelli et al., 1997; Miller et al., 2009;
Sprinzak et al., 2010). Differential activity between DLL and JAG ligands
adds further nuance to Notch signaling; in cells expressing “fringe”
genes (lunatic fringe, manic fringe or radical fringe), Notch receptors
are modiﬁed such that DLL ligand strongly activates, but JAG ligand in-
hibits, signaling (Benedito et al., 2009). This many-tiered regulatory ap-
paratus enables the formation of stark boundaries that are essential forthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
392 D. Reichman et al. / Stem Cell Research 17 (2016) 391–400tissue morphogenesis. However, due to the complexity of Notch signal
regulation, interpretation of phenotypes in transgenic mouse and in
vitro gain/loss of function studies can be challenging.
Human embryonic stem cells (hESC) provide an accessible platform
for modeling cardiovascular differentiation in vitro, thus permitting the
interrogation of signaling pathways that are speciﬁcally active in
embryonic endothelium. Moreover, hESC-derived ECs can recapitulate
fundamental cellular events, like EndMT, that occur uniquely in devel-
opmental and/or pathological contexts. We have previously developed
culture conditions that promote cardiovascular differentiation of
hESCs and identiﬁed signalingpathways that affect trans-differentiationFig. 1. hESC-derived ECs undergo EndMT in puriﬁedmonolayer culture. (a) VPr-mOrange hESC
hESC-derived ECs were isolated by FACS following differentiation and cultured inmonolayer; fo
identity (b) and EndMT (c). (d–f) hESC-ECs were isolated and plated at variable cell densities
speciﬁc for α-SMA; (e and f) the percentage of α-SMA+ cells was quantiﬁed in EC cultures p
(b, c and f) represent standard deviation of experimental values performed in triplicate. Erro
triplicate; * - p b 0.01 relative to 1 K and 5 K densities. The stroke box in (d) is shown at higheof hESC-derived ECs to mesenchymal fate (James et al., 2010). In this
study, we generated hESC-derived ECs that exhibited multiple hall-
marks of EndMTwhen sustained inmonolayer culture. Phenotypic tran-
sition of hESC-ECs was Notch dependent, and mediated by a positive
feedback circuit in which activation of Notch resulted in upregulation
of DLL4 ligand and subsequent activation of Notch in neighboring
cells. Upon reaching a critical threshold of Notch signal activation in
high-densitymonolayer culture, EndMTwas initiated in cells exhibiting
increased surface expression of JAG1, which combined with elevated
cis-expression of DLL4 to exert an inhibitory role on Notch activation.
These ﬁndings expand upon the previously documented interplays were subjected to a cardiovascular differentiation protocol on vascular feeders. (b and c)
llowing 1, 3 and 5 days of culture, transcript levels weremeasured for genes related to EC
; EC cultures plated at high density were labeled with a ﬂuorophore-conjugated antibody
lated at variable densities following 5 days of monolayer culture (e and f). Error bars in
r bars in (b, c and f) represent standard deviation of experimental values performed in
r magniﬁcation at the right. Scale bar – 100 μm.
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vasculogenesis and integrate a novel signaling mechanism for EndMT
in hESC-derived ECs.
2. Results
2.1. hESCs-derived ECs undergo EndMT in puriﬁed monolayer culture
We have previously developed tools for the robust differentiation
and speciﬁc identiﬁcation of ECs from hESCs (James et al., 2010; James
et al., 2011). These studies revealed signiﬁcant trans-differentiation po-
tential of hESC-ECs, which was mitigated by inhibition of TGFβ signal-
ing. To deﬁne the ontogeny of mesenchymal cells that emerge from
hESC-ECs, we subjected hESCs to a cardiovascular differentiation proto-
col (Fig. 1a) and puriﬁed resultant ECs after 12 days for extended
growth in monolayer culture. Transcriptional proﬁling of puriﬁed
hESC-EC cultures at two day intervals beginning the day after initial
plating revealed increased expression of EC-speciﬁc genes (Fig. 1b), as
well as genes that have been linked to EndMT and pericytic identity
(Fig. 1c). Staining for α-Smooth Muscle Actin (α-SMA) identiﬁed re-
gions of EndMT that were evident as primary cultures reached conﬂu-
ence (Fig. 1d). Notably, increased initial plating density of hESC-ECsFig. 2. Notch inhibition enhances yield and purity of hESC-derived ECs. (a and b) Beginning at
DAPT and/or the ALK4/5/7 inhibitor SB431542; at day 14 representative confocal micrograp
distribution of ECs (black). (c) VPr-mOrange hESCs were differentiated with DAPT included in
10 to 14); following 14 days the relative percentage (white) and number (black) of VP
supplemented with VEGF-A alone, or VEGF-A and DAPT for days 5 to 14 were stained for α-SM
control conditions, the VPr+CD31+ EC population was puriﬁed by FACS and plated at an in
medium supplemented with VEGF-A alone or VEGF-A and DAPT, total EC number (e) and pe
Error bars in (b, c, e and f) represent standard deviation of experimental values performed in
scale bar in (d) – 100 μm.resulted in an elevated proportion of derivatives expressing α-SMA
after 5 days (Fig. 1e and f). These data afﬁrm the capacity for hESC-ECs
to undergo EndMT and reveal initial plating density as a critical modu-
lator of EC transdifferentiation.
2.2. Notch signal inhibition enhances yield and purity of hESC-derived ECs
Notch signaling, which is activated by membrane bound ligand/re-
ceptor interactions, is known to play a central role in EndMT during em-
bryonic cardiogenesis, and was thus a likely mediator of EndMT in
hESC-ECs. To assess the functional contribution of Notch signal activa-
tion to the EndMT of hESC-ECs, we differentiated hESCs in the presence
of SB431542 and DAPT, small molecule inhibitors of TGFβ and Notch
signaling, which are both known to play a role in EndMT. Inhibitors
were added beginning at 8 days of differentiation and by day 14, addi-
tion of DAPT increased vascular density within organoid differentiation
cultures (Fig. 2a). Flow cytometric analysis revealed that SB431542 in-
creased the total number of hESC-derived cells, while DAPT increased
the number and proportion of total ECs among hESC-derivatives
(Fig. 2b). To determine when during differentiation Notch inhibition
confers a beneﬁt, we exposed cultures to DAPT during three discreet
windows loosely correlating to mesoderm induction, vascular8 days of differentiation, VPr-mOrange hESCs were exposed to the Notch signal inhibitor
hs showed the extent of VPr+ cells (a) and ﬂow cytometry (b) quantiﬁed the relative
growth media within one or more temporal windows (days 0 to 5, days 5 to 10, or days
r+ ECs in resultant cultures was measured by ﬂow cytometry. (d) Day 14 cultures
A by immunoﬂuorescence. (e and f) Following differentiation of VPr-mOrange hESCs in
put of sixty thousand cells per well of a 6-well dish; following ﬁve days of growth in
rcentage of CD31+ and α-SMA+ cells (f) was quantiﬁed by intracellular ﬂow-cytometry.
triplicate; * - p b 0.01. The insets in (a) shows a brightﬁeld view. Scale bar in (a) – 1 mm;
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age and number of VPr+ ECs were enriched when DAPT was included
during intermediate and late temporal windows. Under these growth
conditions, immunoﬂuorescence revealed few α-SMA+ cells, while
control cultures supplemented with VEGF-A alone exhibited wide-
spread α-SMA+ cells (Fig. 2d). Upon isolation and monolayer culture
of VPr+ ECs, supplementing growth medium with DAPT increased the
overall number of ECs after 5 days (Fig. 2e), and increased the percent-
age of ECs in outgrowths at the expense ofα-SMA+ cells (Fig. 2f). Taken
together, these data suggest that inhibition of Notch signaling increased
the number and proportion of ECs in hESC differentiation cultures by
promoting proliferation, and preserving vascular cell identity.
2.3. Transitional ECs exhibit increased JAG1 expression and reduced Notch
activation
To deﬁne spatial distribution and expression levels of Notch ligands
during EndMT, we used ﬂuorophore-conjugated antibodies to localize
DLL4 and JAG1 ligands in conﬂuent monolayers of hESC-derived ECs
(Fig. 3). Isolated α-SMA+ derivatives of EndMT displayed elevated sur-
face expression of JAG1 (Fig. 3a) and increased expression of PDGFRβ
(Fig. 3b), with reduced nuclear localization of the Notch target HEY1
in JAG1high cells (Fig. 3c). To provide some indication of the level of
Notch activation during EndMT, hESC-ECs were incubated for 30 min
with ﬂuorophore-conjugated antibodies against DLL4 and JAG1 in live
cell cultures, then washed with PBS and returned to culture media.
This enabled a crude measure of ligand internalization in signal-pre-
senting cells and revealed that DLL4-mediated activation was reduced
in transitional hESC-ECs, which displayed a VPrlowDLL4negJAG1high phe-
notype (Fig. 3d). Additionally, hESC-ECs surrounding zones of EndMT
showed relatively reduced DLL4 internalization, suggesting that loss of
DLL4 activity nucleated a wave of reduced Notch activation that radiat-
ed outward from transdifferentiating ECs. Immunocytochemistry re-
vealed the cellular localization of Notch1 intracellular domain (Notch1
ICD), thus providing a surrogate measure of Notch pathway activation.
Notch1 ICD was enriched in nuclei of subconﬂuent hESC-ECs (Fig. 3e),
but was relatively reduced in nuclei of conﬂuent or transitional hESC-
ECs (Fig. 3f). To further assess the change in Notch signal activation
upon transition to mesenchymal phenotype, the VPr+CD31+ and
CD31negPDGFRβ+ populations were FACS sorted from monolayer cul-
tures following phenotypic transition and endothelial, mural and
Notch-related transcripts were measured by qPCR (Fig. 3g). Relative to
the CD31+ fraction, PDGFRβ+ cells showed markedly reduced (10–
100 fold) levels of transcripts reﬂecting Notch activation (DLL4,
NOTCH1, NOTCH4, HEY1) and EC identity (CD31, VEGFR2, CDH5), and
increased levels of mural cell markers (CALPONIN, PDGFRβ) and SLUG,
a key transcription factor governing EndMT.
2.4. Jagged1 knockdown induces accelerated Notch activation feedback and
EndMT
The interplay of DLL4 and JAG1 in differential activation of Notch sig-
naling has beenpreviously noted (Benedito et al., 2009), withweak-act-
ing JAG1 effectively inhibiting DLL4-mediated Notch activation in ECs
expressing Fringe genes. To determine whether elevated surface ex-
pression of JAG1 in transitional ECs may reﬂect a competitive interplayFig. 3. Transitional ECs exhibit increased JAG1 expression and reduced Notch activation. (a and
labeledwith ﬂuorophore conjugated antibodies speciﬁc for CD31 (red),α-SMA (green), Jagged1
conjugated antibodies speciﬁc for CD31 (red), Jagged1 (blue) and HEY1 (green). (d) Following
(blue) were added directly to culture media at 37 °C; after 30 min, cells were washed thre
imaged by confocal microscopy. (e and f) In sub-conﬂuent (e) and conﬂuent (f) cultures
intracellular domain and CD31; arrows in the inset indicate nuclei and asterisk in (f) shows C
with antibodies speciﬁc for CD31 and PDGFRβ; the CD31+PDGFRβneg and CD31negPDGFRβ+
Error bars in (g) represent standard deviation of experimental values performed in triplicat
shown at higher magniﬁcation in the inset. Scale bars in (a–f) – 100 μm.between Notch ligands, we used multiple lentiviral shRNAs to target
DLL4 and JAG1 gene products (Fig. 4 and Supplementary Fig. 1). Relative
to control shRNA, DLL4 and JAG1 shRNAs reduced their targets at the
transcript (Fig. 4a and Supplementary Fig. 1a) and protein (Fig. 4b–d)
levels. Notably, while knockdown of DLL4 resulted in relatively less
JAG1 transcript and protein, knockdown of JAG1 resulted in nearly
two-fold increase in DLL4 transcript/protein. Knockdown of JAG1 also
promoted increasedNOTCH1 ICDnuclear enrichment, even in conﬂuent
hESC-EC cultures, and increased the frequency of CD31neg cells (Fig. 4e).
Puriﬁed ECs treated with shRNAs (Fig. 4f and g) or DAPT (Fig. 4f) were
analyzed by qPCR on successive days, revealing an accelerated elevation
of DLL4, Notch1/4 and HEY1 transcripts in cells transduced with JAG1
shRNA (Fig. 4f). Notably, the transcript level of Jagged2 was elevated
3-fold in response to JAG1 shRNA, perhaps reﬂecting a compensatory
function in these cells. Consistent with activation of Notch signaling
being correlated with arterial identity, cells treated with DLL4 shRNA
or DAPT showed reduced expression of the arterial surface marker
EPHRINB2 while JAG1 shRNA induced a reduction in the venous tran-
scription factor COUPTFII (Fig. 4g, left). Markers of mural cell identity
(PDGFRβ, NOTCH3, CALPONIN) and EndMT (SLUG) were increased in
response to JAG1 shRNA relative to controls (Fig. 4g, middle), and
remained relatively low in DLL4 shRNA or DAPT-treated cells. Notably,
effectors of TGFβ signaling were differentially regulated in response to
JAG1 shRNA (Fig. 4g, right) – BMPER, which has been shown to antago-
nize BMP/GDF signaling (Moser et al., 2003), wasminimally, though sig-
niﬁcantly increased, while endoglin, a co-receptor that enables
activation of BMP/GDF signaling in response to TGFβ1 in ECs (Lebrin
et al., 2004),was reduced. Finally, JAG1 shRNA induced elevated expres-
sion of GUCY1A3, GUCY1B3 and INHIBINA, which together with IGF2
enable nitric oxide signaling and EndMT in cardiac cushions down-
stream of Notch activation (Chang et al., 2011). Together, these data
suggested a role for JAG1 inmitigating Notch signal activation in mono-
layer ECs, and demonstrated increased signaling feedback and EndMT
following knockdown of JAG1.2.5. Hyper-activation of Notch signaling promotes DLL4-mediated cis-inhi-
bition and EndMT
Notch ligands are membrane bound, and ligand internalization by
signal-presenting cells is an important factor in NICD internalization
within the signal-receiving cell (Parks et al., 2000). Moreover, in sig-
nal-presenting cells ligands can inhibit, instead of activate, Notch recep-
tors in a cell-autonomous fashion (cis-inhibition) (de Celis and Bray,
1997; Klein et al., 1997; Micchelli et al., 1997; Miller et al., 2009;
Sprinzak et al., 2010). To deﬁne the relative contribution of cis- versus
trans-presentation of Notch ligands to the phenotypes observed in our
system, we speciﬁcally over-expressed DLL4 cDNA in a population of
hESC-derived ECs and co-cultured these cells with an even input of
cells that were clonally labeled with blue ﬂuorescent protein (BFP,
Fig. 5). Overexpression of DLL4 cDNA had a stark dose-dependent effect
on the total cell number (Fig. 5a) and percent yield (Fig. 5b) of hESC-de-
rived ECs, without an evident increase in apoptotic cells (data not
shown). In combined monolayer cultures, the ratio of signal-receiving
(SR, blue) to signal-presenting (SP, grey) was slightly skewed in favor
of SR cells at all-time points, however, after 6 days, knockdown of
JAG1 reduced cell number in SR cells, as well as in control SP cellsb) Following 5 (a) or 6 (d) days of growth in puriﬁed monolayer culture, hESC-ECs were
(blue) and PDGFRβ (grey). (c) Following 4 days hESC-ECswere labeledwith ﬂuorophore-
5 days of growth, ﬂuorophore conjugated antibodies speciﬁc for DLL4 (green) and JAG1
e times with PBS, incubated with warm growth medium for 15 min at 37 °C and then
of hESC-ECs, cells were ﬁxed and labeled with an antibody speciﬁc for the NOTCH1
D31neg transitional cells. (g) Following 6 days, monolayers were dissociated and labeled
populations were sorted by FACS and qPCR analysis was performed for the genes shown.
e; * - p b 0.01. Brightﬁeld views are shown in (a and d). The stroke box in (c, e and f) is
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on DLL4 surface expression in SR cells, and knockdown of JAG1 magni-
ﬁed this effect (Fig. 5d). Quantiﬁcation of CD31+ and CD31neg cells inthe SR population showed a decrease in total CD31+ cells induced by
overexpression of DLL4 in SP cells, and although high DLL4 in SP cells
promoted a signiﬁcant increase in CD31neg cells within the SR fraction,
Fig. 4. Jagged1 knockdown induces accelerated Notch activation feedback and EndMT. (a–d) Control (Scrambled), JAG1 and DLL4 lentiviral shRNAs were added to hESC-ECs upon
puriﬁcation from day 14 differentiation cultures; following 5 days, qPCR (a) and ﬂow cytometric analyses (b–d) of DLL4 (a, d and d) and JAG1 (a, c and d) were performed. (e)
Conﬂuent hESC-EC cultures that had been transduced with Control or JAG1 shRNA were labeled with antibodies speciﬁc for NOTCH1 intracellular domain and CD31; arrowheads
indicate nuclei and asterisks show CD31neg transitional cells. (f) At 1, 3 and 5 days following addition of Control, DLL4 or JAG1 lentiviral shRNAs, transcriptional analysis of Notch
related genes was performed by qPCR. (g) At 2, 4 and 6 days following addition of lentiviral shRNAs or DAPT, qPCR analysis was performed for the genes shown. Error bars in (a, d, f
and g) represent standard deviation of experimental values performed in triplicate; * - p b 0.01. Scale bars in (e) – 100 μm.
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Fig. 5. Hyper-activation of Notch signaling promotes DLL4-mediated cis-inhibition and EndMT. (a and b) Following FACS isolation at day 14, hESC-ECs were transduced with lentiviral
vectors driving constitutive expression of control (Empty) or DLL4 cDNA sequences; the number (a) and percentage (b) of CD31+ cells was measured by ﬂow cytometry for increasing
viral titers of DLL4 cDNA at 3 and 5 days following addition of lentiviral particles. (c–e) hESC-ECs were isolated from either blank VPr-mOrange hESCs (signal presenting cells, grey) or
VPr-mOrange hESCs that had been clonally labeled with BFP (signal receiving cells, blue); unlabeled ECs were transduced with control or DLL4 cDNA (500 pg titer), and BFP+ ECs
were transduced with control or JAG1 shRNAs. Equal numbers of signal presenting and signal receiving cells were combined and ﬂow cytometry was used to quantify the total cell
number (c), mean ﬂuorescence intensity of surface DLL4 on ECs (d) and total CD31+ and CD31neg cells (e) at 4, 5 and 6 days post co-culture. (f) Schematic model outlining feedback
of Notch signal activation on elevated expression of Notch ligands/receptors and, ultimately, cis-inhibition in cells expressing high levels of DLL4. Error bars in (a–e) represent standard
deviation of experimental values performed in triplicate; * - p b 0.01.
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398 D. Reichman et al. / Stem Cell Research 17 (2016) 391–400thiswas augmented by knockdown in JAG1 (Fig. 5e). Together, these re-
sults suggest that trans-activation of Notch signaling reduces EC expan-
sion and, at high levels that are enabled by loss of JAG1 inhibitory
function, promotes increased EndMT.
3. Discussion
During development, dysregulation of Notch signaling results in car-
diovascular anomalies, and Notch signaling effectors are essentialmedi-
ators of EndMT (Niessen and Karsan, 2008). Previous studies have
identiﬁed inter-ligand competition (Benedito et al., 2009), post-transla-
tional modiﬁcations (Panin et al., 1997) and divergence in cis versus
trans ligand activity (de Celis and Bray, 1997; Klein et al., 1997;
Micchelli et al., 1997; Miller et al., 2009; Sprinzak et al., 2010) asmodu-
lators of Notch signal activation, yet few studies, to date, have interro-
gated the interplay of Notch ligands in the context of EndMT. Here, we
have generated a hESC-derived EC population that is capable of recapit-
ulating EndMT in monolayer culture, and utilized this platform to dem-
onstrate a role for Notch signal hyper-activation in promoting EndMT.
Trans-activation of Notch in hESC-derived ECs increased expression of
DLL4 and NOTCH1/4, resulting in population level positive feedback in
Notch activation. Competitive inhibition of Notch activation by JAG1 co-
incided with acquisition of mesenchymal phenotype, yet JAG1 knock-
down promoted unrestrained activation of Notch signaling,
upregulation of cis-inhibitory DLL4 and, ultimately, increased EndMT.
These ﬁndings integrate a novel cellular mechanism of EndMT into the
continuously evolving paradigm of Notch signaling during cardiovascu-
lar development and may contribute to therapeutic approaches for
modulation of angiogenesis in regenerative and/or pathological
contexts.
During vasculogenesis, the coupling of growth and patterning with-
in the primitive vascular plexus ismediated by crosstalk between Notch
and VEGF signaling. Activation of Notch in ECs results in downregula-
tion of VEGFR2 (Taylor et al., 2002), thus restraining proliferation and
inducingmaturation in an angiogenic context. During retinal neovascu-
larization, inhibition of Notch using DAPT results in enhanced EC
sprouting and a dense vascular plexus (Benedito et al., 2009). Inhibition
of Notch signaling has also been shown to augment yield of ECs during
hESC differentiation (Sahara et al., 2015), with the beneﬁt attributed to
increased conversion of cardiovascular precursors to EC progenitors
that have higher proliferative potential than mature ECs. Similarly, we
show here that blockade of EC maturation via Notch inhibition can ex-
tend the proliferative lifespan of hESC-derived ECs, and we have elabo-
rated amechanism bywhich increased EC number derives, in part, from
reduced EndMT.
Induction of EndMT results from integration of multiple extrinsic in-
puts within the dynamically shifting cellular environment of
cardiogenesis. Owing to the membrane bound presentation of ligands,
Notch signaling status is dependent on the organization and distribu-
tion of signal-presenting and signal-receiving cells. Conversely, the
TGFβ pathway acts through a diversity of secreted morphogens, but
has also been shown to play a pivotal role in EndMT (Gonzalez and
Medici, 2014). Knockout of the type I receptor, ALK5, which responds
to TGFβ1 ligand by activation of SMAD2/3, results in failure of EndMT
induction from endocardium (Sridurongrit et al., 2008); and in hESC-
derived ECs activation of SMAD2/3 induces phenotypic transition that
can be mitigated by co-culture with the ALK4/5/7 inhibitor SB431542
(James et al., 2010). In this study, we found increased expression of
BMPER, and decreased expression of endoglin in conditions that
promote EndMT of hESC-derived ECs (Fig. 4f). BMPER antagonizes
BMP signaling (Moser et al., 2003) and endoglin augments TGFβ signal
activation by enabling ECs to respond to TGFβ1 ligand via activation of
an ALK1:SMAD1/5/8 axis instead of a ALK5:SMAD2/3 axis (Lebrin
et al., 2004). Hence, the shift from endoglin to BMPER expression in
conﬂuent hESC-ECs denotes a change from SMAD1/5/8 activation to
SMAD2/3 activation, and may account, in part, for reduced EC numberand increased EndMT. Indeed, ALK1 (Urness et al., 2000) or endoglin
(Sorensen et al., 2003) loss of function in mice results in aberrant cardi-
ac cushion formation and, in vitro, induces a shift in cultured ECs from
proliferation to growth arrest (Lebrin et al., 2004). Our data revealed
an increase in BMPER expression even in control conditions, but
endoglin was uniquely reduced upon JAG1 knockdown. Although
TGFβ signaling functions independently to promote EndMT, these re-
sults may reﬂect crosstalk between Notch and TGFβ signaling to en-
hance SMAD2/3 activation at the expense of SMAD1/5/8 activation.
Another pathway that has been linked to Notch is Nitric oxide (NO)
signaling. NO signaling is a critical modulator of cardiac function
(Rastaldo et al., 2007) and deﬁciency in NO generation in embryonic
mice (Aicher et al., 2007; Feng et al., 2002; Lee et al., 2000) results in
major cardiac anomalies that are similar to those displayed by human
patients carrying Notch1 mutations (Garg et al., 2005). Chang et al.
have linked Notch to activation of to an autocrine loop consisting of
GUCY1A3, GUCY1B3, ACTIVINA and IGF2, which enables propagation
of nitric oxide signaling, and ultimately EndMT in embryonic mouse
heart (Chang et al., 2011). All of these factors were elevated in hESC-de-
rived ECs under conditions that promoted EndMT (Fig. 4f), afﬁrming
that multiple signaling elements present during embryonic EndMT are
recapitulated in our in vitro platform.
Despite being linked tomultiple downstreameffectors of EndMT, in-
cluding NO signaling (Chang et al., 2011) and SLUG (Niessen et al.,
2008), the molecular mechanisms that tip the balance of Notch signal
activation leading up to EC trans-differentiation are not well deﬁned.
The increased surface expression of JAG1 observed in cells undergoing
EndMT and coincident reduction in DLL4 expression (Fig. 3) suggested
a role for JAG1 in attenuatingNotch activation. Benedito et al. have dem-
onstrated the role of JAG1 in designating tip versus stalk phenotype of
ECs during retinal neo-vascularization (Benedito et al., 2009). In mice
with EC-speciﬁc loss of JAG1, progression of the retinal vascular plexus
ismarked by reduced EC proliferation, elevated DLL4 expression and in-
creased stalk to tip cell ratio. This phenotype arises from loss of JAG1-
mediated Notch inhibition in ECs expressing Fringe genes. Similarly,
our knockdown of JAG1 in hESC-derived ECs resulted in decreased cell
counts and increased Notch activation/DLL4 expression, as well as in-
creased EndMT. Although not emphasized in their study, Benedito et
al. noted increased pericyte coverage and ectopic localization of vascular
smooth muscle cells to venules in JAG1 loss-of-function mice. Because
EC-speciﬁc loss of JAG1 in these mice may be partially rescued by sur-
rounding non-endothelial cells, this phenotype may be a milder corre-
late to the effect observed in our in vitro platform, in which JAG1 loss
of function was uniformly applied across a puriﬁed population of ECs.
The elevation of JAG1 surface expression in transitional ECs suggests
that it plays a role in phenotypic transition of these cells. Overexpres-
sion of activated JAG1 cDNA in cultured human microvascular ECs
activated a SMA-promoter driven luciferase and induced trans-differen-
tiation to vascular smooth muscle cells (Noseda et al., 2004). Elevation
of JAG1 during wound healing can function to attenuate activation of
Notch signaling (Pedrosa et al., 2015) and expression proﬁling of
CD31+ ECs and CD31negPDGFRβ+ derivatives of EndMT revealedmark-
edly reduced expression of genes related to Notch activation (Fig. 3e).
Yet JAG1 is likely not the sole actor in reducing Notch pathway activa-
tion, as JAG1 knockdown leads to increased, instead of decreased
EndMT. Here, we showed that increased Notch activation, as reﬂected
by expression of Notch target DLL4, correlates with the degree of
EndMT in hESC-EC monolayers (Fig. 5d and e). Previous work in Dro-
sophila has identiﬁed the potential for Delta (DLL4 orthologue) to inhib-
it Notch on its own cell (de Celis and Bray, 1997; Klein et al., 1997;
Micchelli et al., 1997; Miller et al., 2009), and Sprinzak et al. have
modeled cis- and trans- activity of human DLL1-Notch1 in live cells
using real time ﬂuorescence microscopy (Sprinzak et al., 2010). This
system revealed that while the response to trans-DLL1 is graded, inhib-
itory action of cis-DLL1 is sharp and occurs at aﬁxed threshold, irrespec-
tive of trans-DLL1 activity. Thus, JAG1 may contribute to attenuation of
399D. Reichman et al. / Stem Cell Research 17 (2016) 391–400Notch activation in hESC-ECs, but cis-inhibitory activity of DLL4 at a crit-
ical threshold of Notch hyper-activation likely accounts for the abrupt
shift in Notch signaling status during EndMT.
Given the technical and bioethical hurdles associated with the study
of human embryogenesis, a human cell-basedmodel that approximates
in vivo cardiogenesis provides unique insight into the cellular/molecu-
lar bases of cardiac anomalies. Moreover, mounting evidence supports
a role for EndMT inwoundhealing and a broad array of pathological dis-
ease processes, including pulmonary (Arciniegas et al., 2005), intestinal
(Rieder et al., 2011), cardiac (Zeisberg et al., 2007) and kidney ﬁbrosis
(Zeisberg et al., 2008). EndMT has also been identiﬁed as a critical me-
diator of neo-intima formation following coronary artery bypass
grafting (Cooley et al., 2014) and has even been implicated in the ad-
vance of atherosclerosis in a mouse model of cardiovascular disease
(Chen et al., 2015). Our results establish an in vitro model of embryonic
EndMT using hESC-derived ECs, and utilize this platform to integrate EC
membrane-bound Notch signaling inputs (DLL4) with pathway activa-
tion status and the initiation of EndMT. Understanding of the signaling
mechanisms that regulate EC identity and its organization intomulticel-
lular vascular channels will be vital to implementing hESC-based vascu-
lar applications, and insight into molecular inﬂuences that mediate
embryonic EndMT may provide fertile ground for therapeutic targeting
of pathways that contribute to degenerative disease and organ/tissue
ﬁbrosis.
4. Materials and methods
4.1. Human ESC culture
Experiments in this report were performed using WMC-2 hESC
(James et al., 2010). The permissions for use of these cell lines were ob-
tained after comprehensive review by the Cornell-Rockefeller-Sloan
Kettering Institute ESCRO committee. The funding for execution of
these studies was secured from approved non-federal funding re-
sources. Human ESC culture medium consisted of Advanced DMEM/
F12 (Gibco) supplemented with 20% Knockout Serum Replacement
(Invitrogen), 1× non-essential amino acids (Gibco), 1× L-Glutamine
(Invitrogen), 1× Pen/Strep (Invitrogen), 1× β-Mercaptoethanol
(Gibco), and 4 ng/ml FGF-2 (Invitrogen). Human ESCs were maintained
on Matrigel™ using hESC medium conditioned by mouse embryonic ﬁ-
broblasts (MEF, Chemicon).
4.2. Lentiviral vectors and transduction
The cDNA sequences for AdE4ORF1, DLL4 and BFP were cloned into
the pCCL-PGK lentivirus vector. Scrambled, Dll1 and Jagged1 speciﬁc
shRNA constructswere cloned into the pLKO vector. Lentiviruswas gen-
erated by co-transfecting 15 μg of our gene of interest lentiviral vector,
3 μg of pENV/VSV-G, 5 μg of pRRE, and 2.5 μg of pRSV-REV in 293 T
cells by the calcium precipitation method. Supernatants were collected
40 and 64 h after transfection as previously described (Naldini et al.,
1996). Viral supernatants were concentrated by ultracentrifugation.
4.3. Generation of PGK-BFP/VPr-mOrange hESC lines
Two passages after addition of PGK-BFP lentiviral particles to VPr-
mOrange hESCs, Accutasewas used to form single cells, whichwere iso-
lated and expanded in the presence of the ROCK inhibitor Y-27632 to
formmultiple parallel cultures and clones expressing clearly detectable
levels of BFP were selected for experimentation.
4.4. EC feeder differentiation
VPr-mOrange hESCs were differentiation on vascular feeders as pre-
viously described (Raﬁi et al., 2013). Brieﬂy, human umbilical vein en-
dothelial cells were isolated and transduced with lentiviral AdE4ORF1to generate durable PEC feeders (Seandel et al., 2008). One day in ad-
vance of plating hESCs on E4ORF1+ primary human umbilical vein en-
dothelial cells (PECs), MEF conditioned medium was replaced with
hESC culture medium without FGF-2 and supplemented with 2 ng/ml
BMP4. The next day, hESCs were onto an 80% conﬂuent layer of
E4ORF1+ PEC in hESC culture medium (without FGF-2, plus 2 ng/ml
BMP4) and left undisturbed for 48 h. At this point, cultureswere consid-
ered as differentiation day zero and cells were sequentially stimulated
with recombinant cytokines in the following order: day 0 to 7 supple-
mented with 10 ng/ml BMP4; day 2 to point of harvest supplemented
with 10 ng/ml VEGF-A; day 2 to point of harvest supplemented with
5 ng/ml FGF-2; day 7 to point of harvest supplemented with 10 μM
SB-431542, unless otherwise stated.
4.5. Flow cytometry and sorting
Flow cytometric analysis and sortingwas performed on a FACSAriaII
(BD). Antibodies used were speciﬁc for CD31 (BD), α-SMA (R&D) and
DLL4 (Biolegend) and Jagged1 (R&D). Data was analyzed using FACS
Diva software.
4.6. Quantitative PCR
Total RNAwas prepared from cultured cells using the RNeasy extrac-
tion kit (Qiagen) and reverse transcribedusingQuantitect Reverse Tran-
scription Kit (Qiagen) according to the manufacturer's instructions.
Relative quantitative PCR was performed on a 7500 Fast Real Time
PCR System (Applied Biosystems) using SYBR Green PCR mix (Applied
Biosystems). Human speciﬁc SYBR green primer pairs used were:
BMPER: f, 5′-aggacagtgctgccccaaatg-3′, r, 5′-tactgacacgtcccctgaaag-
3′;
CALPONIN: f, 5′-gagtcaacccaaaattggcac-3′, r, 5′-ggactgcacctgtgtatggt-
3′;
CD31: f, 5′-gacgtgctgttttacaacatctc-3′, r, 5′-cctcacgatcccaccttgg-3′;
COUP-TFII: f, 5′-ccgagtacagctgcctcaa-3′, r, 5′-ttttcctgcaagctttccac-3′;
DLL4: f, 5′-aactgcccttcaatttcacct-3′, r, 5′-gctggtttgctcatccaataa-3′;
ENDOGLIN: f, 5′-gaattctggtacatctactcgc-3′, r, 5′-ggctatgccatgctgct
ggtgg-3′;
EPHRINB2: f, 5′-ggactggtactatacccacagat-3′, r, 5′-tgtctgcttggtcttt
atcaacc-3′;
GAPDH: f, 5′-ctgatgcccccatgttcgtc-3′, r, 5′-caccctgttgctgtagccaaattc-3′;
GUCYA3: f, 5′-tacaaggtggagaccattggcgat-3′, r, 5′-atccagagtgcag
tccaattcgca-3′;
GUCYB3: f, 5′-ggaaattgctggccaggttcaagt-3′, r, 5′-ttctcctgtggttt
ctgttcggct-3′;
HEY1 – f, 5′-gtgcggacgagaatggaaa-3′, r, 5′-ctggccaaaatctgggaaga-3′;
IGF2: f, 5′-acaccctccagttcgtctgt-3′, r, 5′-gaaacagcactcctcaacga-3′;
INHIBINA: f, 5′-ctcggagatcatcacgtttg-3′, r, 5′-ccttggaaatctcgaaagtgc-3′;
JAGGED1: f, 5′-caacacggtccccatcaag-3′, r, 5′-tacttcagaattgtgtgtcc
ttatttt-3′;
JAGGED2: f, 5′-ggtcgtacttgcactcacaatacc-3′, r, 5′-gtagcaaggcaga
gggttgc-3′;
NOTCH1: f, 5′-ccgcagttgtgctcctgaa-3′, r, 5′-accttggcggtctcgtagct-3′;
NOTCH3: f, 5′-tccagattctcatccgaaaccgct-3′, r, 5′-gggtctcctccttgc
tatcctgcat-3′;
NOTCH4: f, 5′-cccaggaatctgagatggaa-3′, r, 5′-ccacagcaaactgctgacat-3′;
PDGFRβ – f, 5′-agacacgggagaatacttttgc-3′, r, 5′-agttcctcggcatca
ttaggg-3′;
SLUG: f, 5′-agatgcatattcggacccac-3′, r, 5′-cctcatgtttgtgcaggaga-3′;
VE-CADHERIN – f, 5′-tggagaagtggcatcagtcaacag-3′, r, 5′-tctacaat
cccttgcagtgtgag-3′;
VEGFR2: f, 5′-actttggaagacagaaccaaattatctc-3′, r, 5′-tgggcaccatt
ccacca-3′;
qPCR Primers speciﬁc for Lunatic and Manic Fringe were obtained
from Origene. Cycle conditions were: one cycle at 50 °C for 2 min;
1 cycle at 95 °C for 10 min; 40 repeat cycles followed by 95 °C for 15 s
400 D. Reichman et al. / Stem Cell Research 17 (2016) 391–400and 60 °C for 1min. Threshold cycles of primer probeswere normalized
to the housekeeping gene β-Actin and translated to relative values.
4.7. Immunoﬂuorescence
Cells were immunocytochemically stained as previously described
(James et al., 2010). Brieﬂy, samples were permeabilized in PBST and
blocked in 5% donkey serum. Sampleswere incubated for 2 h in primary
antibodies blocking solution, washed 3 times in PBS and incubated in
secondary antibodies (Jackson Laboratories) for 1 h. Following washing
some sections were counterstained for nucleic acids by DAPI
(Invitrogen) before mounting and imaging by confocal microscopy.
The Primary antibodies used for immunostaining were CD31 (BD),
PDGFRβ (BD), α-SMA (R&D), JAGGED1 (R&D), HEY1 (R&D) and
NOTCH1-ICD (R&D). All imaging was performed using a Zeiss 710
META confocal microscope.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.scr.2016.09.005.
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